DALLAS, Aug. 17, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces a stock report featuring Marshall Edwards Inc. (Nasdaq:MSHL). The report briefly notes the company's most recent developments and news, and outlines its financial position, market performance, and comparison against industry peers.
The full report is available at: www.microstockprofit.com/lp/MSHL
Marshall Edwards Inc. (MSHL) is an oncology company focused on the clinical development of novel anti-cancer therapeutics. Its lead programs focus on two families of small molecules that result in the inhibition of tumor cell metabolism. The first and most advanced is a NADH oxidase inhibitor program that includes lead candidate ME-143 (formerly NV-143). The second is a mitochondrial inhibitor program that includes lead candidate ME-344 (formerly NV-344).
This newsletter has been helping traders make great investment decisions on MSHL; click here for a 25% discount offer.
In the report, the analyst notes:
"MSHL shares shot up more than 86% Tuesday as investors cheered the Company's announcement that its Investigational New Drug (IND) application for ME-143 (formerly NV-143) has been approved by the U.S. Food and Drug Administration. ... The Company said it intends to initiate a phase I clinical trial of intravenous ME-143 by September."
"MSHL president and CEO Daniel P. Gold Ph.D. said the IND represents a significant milestone for the MSHL and, more importantly, a critical step forward in the development of a drug candidate that the Company believes has the potential to significantly improve the treatment of patients with cancer."
To read the entire report visit: www.microstockprofit.com/lp/MSHL
See what investors are saying about MSHL at http://www.stockhideout.com
Get breaking news on MSHL at http://thestockmarketwatch.com/
MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.